TP53 mutation. We then selected Nultin-3, which has been investigated as a potential therapeutic agent specifically targeting TP53-mutated cancer cells [16]. Furthermore, we further supplemented with 10 μM Nultin-3 in the previous knockout of CHEK2 HCC cell lines (LM3, Huh7). Subsequent...
The eQTLgen database and two HCC Genome-Wide Association Study (GWAS) datasets (ieu-b-4953, ICD10 C22.0) were used to find the drug target: CHEK2. Next, Colony, Edu, 尾-gal, and cell cycle analysis were facilitated to evaluate the role of CHEK2 knockout in HCC. In addition, Nul...
Article Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American Patient Nataly Shtraizent 1,2, Hiroshi Matsui 3, Alla Polotskaia 1 and Jill Bargonetti 1,* Received: 15 August 2015; Accepted: 2 October ...